A peroxisome proliferator-activated receptor γ antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma

Oncology Reports

Volumn 18, Issue 4, 2007, Pages 825-832

  Kim, Kyung Ryoul ^a   Choi, Ha Na ^a   Lee, Ho Jin ^a   Baek, Hyun A ^a   Park, Ho Sung ^a   Jang, Kyu Yun ^a   Chung, Myoung Ja ^a   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Hepatocellular carcinoma; Peroxisome proliferator activated receptor ; Vimentin

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTIDIABETIC AGENT; BENZAMIDE DERIVATIVE; CHROMAN DERIVATIVE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRIDINE DERIVATIVE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL GROWTH; CELL MOTION; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME IMMUNOASSAY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANILIDES; BENZAMIDES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CHROMANS; COLONY-FORMING UNITS ASSAY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; LIGANDS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; PPAR GAMMA; PYRIDINES; THIAZOLIDINEDIONES; VIMENTIN;

EID: 38449095879     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.4.825     Document Type: Article

References (45)

1. Bosch FX, Ribes J, Cleries R and Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
2. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD and Gallinger S: Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141: 330-339, 2007. (Pubitemid 46371307)
3. Hanazaki K, Kajikawa S, Koide N, Adachi W and Amano J: Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 96: 1243-1250, 2001. (Pubitemid 32319168)
4. Tang ZY: Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 7: 445-454, 2001.
5. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ and Maitland NJ: Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52: 253-263, 2002.
6. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B and Osborn M: p53 protein and vimentin in invasive ductal NOS breast carcinoma - relationship with survival and sites of metastases. Eur J Cancer 30A: 1527-1534, 1994. (Pubitemid 24343016)
7. Gilles C, Polette M, Piette J, Delvigne AC, Thompson EW, Foidart JM and Birembaut P: Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol 180: 175-180, 1996. (Pubitemid 26370184)
8. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP and Sauter G: High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154: 981-986, 1999. (Pubitemid 29169731)
9. Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, Huang M, Wang Y, Wu MC, Huang JF, Zeng WF, Sham JS, Yang M and Guan XY: Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23: 298-302, 2004. (Pubitemid 38142264)
10. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H and Auwerx J: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779-18789, 1997. (Pubitemid 27318225)
11. Blanquart C, Barbier O, Fruchart JC, Staels B and Glineur C: Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85: 267-273, 2003. (Pubitemid 37011102)
12. Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9, 2003.
13. Puddu P, Puddu GM and Muscari A: Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? Int J Cardiol 90: 133-140, 2003. (Pubitemid 37087868)
14. Chawla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800, 1994. (Pubitemid 24241266)
15. Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
16. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
17. Sarraf P, Mueller E, Jones D, King FJ, De Angelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052,1998. (Pubitemid 28417337)
18. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998. (Pubitemid 28371075)
19. Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60: 1129-1138, 2000.
20. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I and Kohgo Y: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455: 135-139, 1999. (Pubitemid 29322796)
21. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H and Mori M: A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50: 563-567, 2002. (Pubitemid 34638879)
22. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M and Sata M: Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33: 1087-1097, 2001. (Pubitemid 32378207)
23. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R and Auwerx J: Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4: 1053-1057, 1998. (Pubitemid 28417338)
24. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA and Evans RM: Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat Med 4: 1058-1061, 1998.
25. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC and Saubermann LJ: Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 65: 2251-2259, 2005. (Pubitemid 40490134)
26. Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T, Kogo M and Kamisaki Y: Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 11: 4012-4021, 2005. (Pubitemid 40791564)
27. Kim DG, Park SY, Kim H, Chun YH, Moon WS and Park SH: A comprehensive karyotypic analysis on a newly established sarcomatoid hepatocellular carcinoma cell line SH-J1 by comparative genomic hybridization and chromosome painting. Cancer Genet Cytogenet 132: 120-124, 2002. (Pubitemid 34170869)
28. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Rocken C, Malfertheiner P and Farrell GC: Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43: 134-143, 2006. (Pubitemid 43733600)
29. Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y and Okumura T: Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 108: 41-46, 2004. (Pubitemid 37444441)
30. Takashima T, Fujiwara Y, Hamaguchi M, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Higuchi K and Arakawa T: Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma. Oncol Rep 13: 601-606, 2005.
31. Takahashi H, Fujita K, Fujisawa T, Yonemitsu K, Tomimoto A, Ikeda I, Yoneda M, Masuda T, Schaefer K, Saubermann LJ, Shimamura T, Saitoh S, Tachibana M, Wada K, Nakagama H and Nakajima A: Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci 97: 854-860, 2006. (Pubitemid 44151265)
32. Nomura S, Nakajima A, Ishimine S, Matsuhashi N, Kadowaki T and Kaminishi M: Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. J Exp Clin Cancer Res 25: 443-448, 2006. (Pubitemid 44763737)
33. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T and Koutselinis A: Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36: 249-255, 2002. (Pubitemid 34497122)
34. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R and Van Oosterom A: A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89: 1409-1412, 2003. (Pubitemid 37386592)
35. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ and Fuchs CS: A phase II study of troglitazone, an activator of the PPAR gamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8: 395-399, 2002.
36. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E and Kantoff PW: Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101: 1569-1574, 2004. (Pubitemid 39318903)
37. Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A and Saubermann LJ: PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int J Cancer 120: 702-713, 2007. (Pubitemid 44969044)
38. Seargent JM, Yates EA and Gill JH: GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 143: 933-937, 2004. (Pubitemid 40065492)
39. Osada T, Sakamoto M, Ino Y, Iwamatsu A, Matsuno Y, Muto T and Hirohashi S: E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. Hepatology 24: 1460-1467, 1996. (Pubitemid 26399050)
40. Hendrix MJ, Seftor EA, Seftor RE and Trevor KT: Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150: 483-495, 1997. (Pubitemid 27073779)
41. Palazzo AF and Gundersen GG: Microtubule-actin cross-talk at focal adhesion. Sci STKE 2002: PE31, 2002.
42. Webber MM, Bello-DeOcampo D, Quader S, Deocampo ND, Metcalfe WS and Sharp RM: Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl) retinamide (4-HPR). Clin Exp Metastasis 17: 255-263, 1999. (Pubitemid 29360904)
43. Yoon WH, Song IS, Lee BH, Jung YJ, Kim TD, Li G, Lee TG, Park HD, Lim K and Hwang BD: Differential regulation of vimentin mRNA by 12-O- tetradecanoylphorbol 13-acetate and all-trans-retinoic acid correlates with motility of Hep 3B human hepatocellular carcinoma cells. Cancer Lett 203: 99-105, 2004. (Pubitemid 37506089)
44. Byun Y, Chen F, Chang R, Trivedi M, Green KJ and Cryns VL: Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8: 443-450, 2001. (Pubitemid 32492764)
45. Eckes B, Dogic D, Colucci-Guyon E, Wang N, Maniotis A, Ingber D, Merckling A, Langa F, Aumailley M, Delouvee A, Koteliansky V, Babinet C and Krieg T: Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci 111: 1897-1907, 1998. (Pubitemid 28370534) Technology Development